

Immunotherapy for non-muscle invasive bladder cancer

Unsworth-White, Samantha; Kitchen, Mark; Bryan, Rik

DOI:
[10.2217/fon-2021-0781](https://doi.org/10.2217/fon-2021-0781)

License:
None: All rights reserved

Document Version
Peer reviewed version

Citation for published version (Harvard):
Unsworth-White, S, Kitchen, M & Bryan, R 2022, 'Immunotherapy for non-muscle invasive bladder cancer: from the origins of BCG to novel therapies', *Future Oncology*, vol. 18, no. 1, pp. 105-115. <https://doi.org/10.2217/fon-2021-0781>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

1 **Abstract**

2 Supplies of intravesical Bacillus Calmette-Guerin (BCG), the first-line treatment for most intermediate-
3 and high-risk non-muscle invasive bladder cancers (IR- and HR-NMIBC), have proven unreliable over
4 the last decade. This review considers the evolution of BCG immunotherapy for NMIBC: from the
5 discovery of the anti-tumour side-effects of Tuberculosis (TB) and subsequently the BCG vaccine, to
6 recent advances in novel immunotherapeutic agents. We summarise the evidence for alternative
7 options to standard intravesical BCG therapy regimens and describe the potential for immune
8 response manipulating drugs in the treatment of NMIBC. These new agents, including immune
9 checkpoint inhibitors, toll-like receptor agonists, and recombinant viral vectors, may provide better
10 options in the management of NMIBC in the future.

11

12 **Lay Abstract**

13 Many patients with non-invasive bladder cancers may need treatments into the bladder, including
14 one called Bacillus Calmette-Guerin (BCG). Unfortunately, the supplies of BCG have been interrupted
15 and somewhat unreliable since 2012. Because of this, we have been forced to look at other means of
16 treating our patients using drugs like BCG. This has made us think about how BCG treatment was first
17 developed more than forty years ago, and how it has evolved as a treatment for bladder cancer. In
18 this article, we review the current uses of BCG and other treatments for bladder cancer, and explore
19 what the future may hold for bladder cancer treatments.

20

21 **(Tweetable abstract – optional):** This review explores the evolution of intra-vesical BCG therapy in IR-
22 and HR-NMIBC. We also describe new and emerging immunotherapeutics in the management of
23 NMIBC, which may become more important if the worldwide shortage of BCG continues.

24

25 **Keywords**

26 Bladder cancer, Bacillus Calmette-Guérin, BCG, Immunotherapy, Review

27

28

29

30

31 INTRODUCTION

32 Bladder cancer is the seventh most common cancer in Western society, with an annual global
33 incidence of >430,000 cases(1). In the UK, we observe >10,000 new cases per year, with an estimated
34 70,000 patients living with bladder cancer at any one time. Greater than 90% are urothelial cell
35 carcinomas (UCC) of the bladder (previously termed transitional cell carcinomas - TCC)(2).

36 Most patients in the UK (75-85%) present with non-muscle invasive bladder cancer (NMIBC: stages
37 Ta/T1/Tis)(3); which represents a spectrum of disease from solitary small tumours with low-risks of
38 recurrence or progression, to large multifocal disease with high-risks of early recurrence or
39 progression to invasive or metastatic disease(4). Such progression to muscle-invasive bladder cancer
40 (MIBC: stages \geq T2) occurs in up to 45% of NMIBC patients(4, 5), and is associated with worse outcomes
41 than if the patient initially presented with MIBC, with a 5-year overall survival rate of only 27-50%
42 despite radical therapies(6, 7). Intravesical Bacillus Calmette-Guérin (BCG) is central to the
43 management of HR-NMIBC, and more recently IR-NMIBC, and has been used for over 40 years to
44 reduce the risks of tumour recurrence and progression (rather than cure)(8). BCG thus represents one
45 of the oldest immuno-oncology (IO) agents in current use. However, there has been a surge in the
46 study and trial setting use of newer IO therapeutics for bladder cancers and other malignancies. In this
47 review, we describe the history of BCG as an IO agent, the current use of BCG for bladder cancer, and
48 the possible future of immunotherapy in bladder cancer.

49

50 BCG PAST: DISCOVERY, DEVELOPMENT & TREATMENT REGIMENS

51 Discovery & Development

52 The journey of discovery of the anti-tumour effects of tuberculosis (TB) to the development of
53 intravesical BCG therapy is a fascinating series of linked events driving clusters of research, leading
54 ultimately to the development of the BCG treatment regimes in use today.

55 In 1925, Dr Thomas Cherry noticed an inverse relationship between the incidence of cancers and
56 tuberculosis (TB). Epidemiological data confirmed that as the incidence of TB declined, more people
57 were dying from cancer(9). These findings were explored further by Dr Raymond Pearl in 1929, who
58 conducted an autopsy series investigating TB lesions in two demographically matched patient groups.
59 He concluded that active TB lesions were more than twice as likely to be present in the no malignancy
60 'control' group (16.3%) compared to the group with malignancies (6.6%)(10). From these findings
61 stemmed the notion of the possible anti-tumour effects of TB.

62 Some 40 years earlier in the 1880s, Louis Pasteur successfully attenuated live strains of cholera and
63 anthrax, and the rabies virus, creating non-virulent forms suitable for vaccination. In 1908, Albert
64 Calmette and Camille Guérin adopted Pasteur's technique to create a successful vaccination against
65 TB, known as *Bacillus Calmette-Guérin* or 'BCG'(11). Calmette and Guérin used isolated
66 *Mycobacterium Bovis* from an infected cow; after 231 passages over 13 years, the bacterium was
67 finally deemed innocuous, creating the live-attenuated BCG vaccine(12). The production of BCG
68 vaccine provided a means for the therapeutic use of the anti-tumour effects of TB in a safer form.

69 Years later in 1959, Lloyd Old carried out the first study demonstrating the anti-tumour action of the
70 BCG vaccine; mice with transplantable tumours given BCG vaccine demonstrated increased resistance
71 to tumour growth compared to non-vaccinated control mice(13). These results supported Cherry's
72 findings 30 years previously of the inverse relationship between the incidence of cancer and TB.

73 In 1966, Coe and Feldman investigated hypersensitivity responses in extracutaneous tissues of guinea
74 pigs. They found that intra-vesical injection stimulated the greatest hypersensitivity response, and
75 although not recognised at the time, this provided early evidence of the potential use for BCG in
76 bladder cancer(14). Following this in 1971, a study by Zbar involving intralesional injections of BCG
77 into hepatocarcinoma-induced guinea pigs, showed that animals injected with BCG did not develop
78 metastases. For optimum effect, it was found that contact between the BCG and tumour cells was
79 needed, and that tumours above a certain size were not effectively treated by BCG(15).

80 Results from these two studies formed the basis from which two concepts were derived:

- 81 1. The anti-tumour effect of BCG was better when restricted to one organ to maximise contact
- 82 2. The dose of BCG must be sufficient for the size of the tumour(s)

83 BCG was first used in the human bladder by deKernion *et al.* in 1975. A patient with an isolated
84 metastasis of a malignant melanoma in the bladder underwent cystoscopic intra-lesional injection of
85 BCG. Cystoscopy confirmed an active area of granulomatous inflammation, and subsequent excision
86 did not identify any residual cancer(16).

87

88 **Treatment Regimens**

89 In 1976, the first intravesical instillation of BCG was performed by Morales. This was a small study of
90 nine patients with a previous history of 22 tumour recurrences in 77 patient-months. Patients received
91 120mg BCG in 50ml saline for each of six instillations administered weekly; following BCG instillation
92 only one recurrence was observed after 41 patient-months(17). Interestingly, this six-week regime
93 arose because the Frappier BCG strain used was packaged in six vials, and because adverse side-effects
94 of this strain diminished within one week, permitting weekly instillation(18). As identified previously
95 by Zbar, a 'sufficient' dose of BCG was required for anti-tumour effects, so taking into account the
96 added dilution from urine within the bladder, the 120mg dose was deemed suitable(18). Amid
97 increasing scientific and clinical interest in BCG therapy for NMIBC, larger studies were undertaken
98 that determined toxicity and efficacy. The US Food and Drug Administration (FDA) subsequently
99 approved the use of intravesical BCG instillation for the treatment of NMIBC in 1990.

100 A meta-analysis conducted in 2002 concluded that BCG not only reduces recurrence of NMIBC but
101 also reduces progression to MIBC(19). With an initial six-week course of BCG deemed safe and
102 effective (what is now termed 'induction' BCG), attention then focused on prolonging the duration of
103 intravesical BCG treatment ('maintenance') in the assumption that further treatment could improve
104 oncological outcomes. Two early studies published in 1987 compared outcomes of patients receiving

105 maintenance therapy to induction alone. Interestingly, neither demonstrated significant differences
106 in rates of tumour recurrence or progression between groups, initially suggesting maintenance
107 therapy was not beneficial, yet increased patient side effects(20, 21). However, small sample sizes,
108 the presence of macroscopic tumour in many cases, and heterogeneity in both the tumour types
109 included and treatment schedules, may have confounded their results. Indeed, a subsequent larger
110 trial with 550 patients was published by Lamm in 2000(22). Here, a more homogenous patient cohort
111 with high-risk non-invasive papillary and carcinoma in situ, who were also macroscopically tumour
112 free, were randomised to receive either induction BCG only or induction plus maintenance BCG
113 (intravesical and percutaneous). The maintenance arm received BCG each week for three weeks at
114 intervals of 3, 6, 12, 18, 24, 30, and 36 months after induction. This study revealed that the median
115 recurrence-free survival was over twice as long for those receiving maintenance therapy (76.8
116 months) compared to those receiving induction only (35.7 months) ($p<0.0001$). Additionally, 5-year
117 survival was 83% in the maintenance arm compared to 78% in the induction only arm confirming the
118 patient benefits of maintenance BCG therapy. Furthermore, a 2003 meta-analysis concluded that
119 toxicity did not differ between patients receiving maintenance therapy and those who do not(23).
120 Therefore, despite increased healthcare costs and patient burden/morbidity, BCG maintenance
121 therapy became incorporated into numerous international guidelines for the treatment of both high-
122 risk, and more recently, intermediate-risk NMIBC(24).

123

124

125

126

127

128 ***[Figure 1 –The evolution of BCG therapy.]***

129 **BCG PRESENT: SHORTAGES & TREATMENT EVOLUTION**

130 **Shortages**

131 There have been several different strains of BCG available, including, but not limited to, Connaught,
132 TICE, Pasteur, Danish, Moreau and Merck. Despite both a recent meta-analysis and review (25, 26)
133 suggesting no superiority of one strain over another in the management of high-risk NMIBC, the
134 Connaught strain appeared to be the most widely used. However, as of July 2012, there has been a
135 worldwide shortage of BCG vaccine - the manufacturers of the BCG Connaught strain shut down
136 temporarily following reports of US FDA regulatory breaches, and later stopped Connaught strain
137 production indefinitely in 2016(27). There are several different strains of BCG available, but limited
138 data comparing their relative efficacy(28). Many centres were forced to use Merck's TICE strain
139 following the Connaught shortage, but a randomised controlled trial in 2014 suggested that TICE
140 may be less effective than Connaught following induction. The Connaught strain was found to have
141 74% 5-year recurrence-free survival compared to 48% for TICE(28). An ongoing large-scale trial (the
142 Southwest Oncology Group (SWOG) S1602), is further evaluating the efficacy of the Tokyo-172 BCG
143 strain, after a smaller 2013 study suggested similar one-year recurrence-free survival to the
144 Connaught strain, *i.e.* superior to TICE for both induction and maintenance(29). In addition, a 2016
145 retrospective study suggested that the Moreau strain had comparable efficacy to those more widely
146 used, with 5-year recurrence-free survival of 65% and progression-free survival of 81%(30).
147 Following this, a retrospective study in 2019 compared BCG TICE with BCG Moreau and found no
148 difference between progression-free and recurrence-free survival, concluding BCG Moreau as an
149 alternative effective substrain for the treatment of NMIBC in a time of shortage(31). SWOG S1602 is
150 also evaluating potential benefit of priming with subcutaneous BCG prior to intravesical BCG to
151 enhance T-cell entry into the bladder mucosa(32). It is clear that further studies are required to
152 evaluate efficacy of alternative strains to help overcome the shortages of the currently-licensed and
153 historically widely-used BCG strains. Notwithstanding, there is little incentive for companies to
154 manufacture BCG - each dose is relatively cheap to purchase, but labour-intensive to produce (three

155 months of culturing and susceptibility to contamination)(33). Since one course of induction BCG
156 therapy (6 instillations) exceeds the dose required to meet the UK's annual BCG vaccination
157 requirements for one year, the shortages have caused major issues with continuing current BCG
158 regimes as a first-line treatment for most IR- and HR-NMIBC(34).

159 For many years, the precise anti-tumour mechanism of BCG has remained unclear and is beyond the
160 scope of this article. However, various recent mechanistic studies have improved our
161 understanding(35, 36) which may prove helpful when investigating adjuncts to BCG use, that could
162 improve efficacy and/or reduce toxicity.

163

164 **Treatment Evolution**

165 BCG shortages continue to impact clinical practice(37). It has therefore been important to investigate
166 possible ways of reducing BCG use whilst maintaining clinical efficacy, specifically, the use of adjunct
167 therapies (in combination with BCG), and modifications to the current standard BCG treatment
168 regimes.

169

170 Combination Therapy

171 Mitomycin C (MMC) is a chemotherapeutic agent that was first found to reduce bladder cancer
172 recurrence following intravesical instillation in 1988(38). Mitomycin C binds and crosslinks DNA
173 through alkylation, preventing DNA synthesis(39). Electromotive drug administration (EMDA) is a
174 recent innovation that enhances drug efficacy by the processes of iontophoresis, electro-osmosis and
175 electroporation(40). When EMDA is utilised to deliver intravesical MMC it is thought that it can
176 penetrate 4-7 times deeper into the bladder mucosa(41), thereby increasing the concentrations of
177 MMC reaching cancer cells. Combinations of BCG and EMDA-MMC instillations have shown promise
178 as an alternative to the full course of both BCG induction and maintenance therapy(42).

179

180 Adapting Treatment Regimens

181 As described by Lamm, the dose-response curve for BCG is bell-shaped, indicating that excessively
182 high concentrations of BCG may worsen outcomes and may paradoxically enhance tumour
183 growth(43). If this curve peak can be determined however, treatment regimes could be optimised
184 further or tailored to each patient, with potentially improved outcomes. Unfortunately however,
185 uncertainty persists over the length and frequency of instillations during maintenance therapy, thus
186 the optimal schedule and length of the maintenance period remains an area of ongoing clinical
187 investigation.

188 **[Table 1:** *A summary of studies investigating different BCG regimens (D = dose, FD = full dose, AE = adverse events).]*

189 Oddens' 2013 RCT, summarised in **Table 1**, describes the potential to reduce the duration of BCG
190 maintenance after comparing three years to one year maintenance(44). For HR-NMIBC patients, three
191 years' full-dose BCG (maintenance) reduced tumour recurrences compared to one year full-dose, but
192 did not reduce disease progression or overall mortality. This trial also evaluated using 1/3 dose BCG
193 for both induction and maintenance; this appeared to have decreased efficacy but without reduced
194 side-effects/toxicity, however, patient drop-out was lower than with higher dose and longer
195 maintenance schedules. This suggests that current practice of three-year maintenance therapy with
196 full-dose BCG could be reduced to improve patient compliance with a small trade-off in reduced
197 efficacy. Furthermore, a reduced-dose regime would reduce financial costs and ensure BCG supplies
198 last longer.

199 Following Oddens' findings, a 2015 CUETO group RCT investigated the efficacy of three year
200 maintenance BCG (BCG instillation once every three months) versus BCG induction only (BCG once-
201 weekly for six weeks)(45). This maintenance schedule reduced the number of BCG instillations from
202 27 (the standard SWOG regimen) to 18. Interestingly, this study suggested that recurrence and
203 progression rates, and overall and cancer-specific survival, were no different between the induction
204 only and induction plus maintenance arms(45). Furthermore, there was lower attrition due to
205 toxicity/side-effects in the induction only arm compared to the maintenance arm (2.6% and 9.9%,
206 respectively). These data suggest that for maintenance therapy to be more effective than induction
207 alone, maintenance instillations must be more frequent than every three months.

208 The 2020 phase III NIMBUS RCT investigated different induction and maintenance BCG instillation
209 frequencies(46). The reduced frequency group received three induction doses at weeks 1, 2 and 6,
210 compared to standard regime of once-weekly dosing for six weeks, and fewer maintenance cycles at
211 weeks one and three of months 3, 6 and 12, compared to the standard weekly dosing for three weeks
212 at months 3, 6 and 12, for one year. Overall, the reduced frequency group received a total of nine BCG
213 instillations, versus 15 for the standard/control group. Although the reduced frequency arm
214 experienced fewer adverse events, the trial was closed early due to a 'safety-relevant difference' in

215 recurrences between treatment arms: 27.1% recurrences after 12 months' median follow-up,
216 compared to 12.0% in the standard BCG arm.

217

218 Alternative Therapies

219 Bladder cancer is said to be 'BCG-unresponsive' when there is persistent or recurrent CIS and/or
220 papillary tumour within 12 months, or recurrent high-grade Ta/T1 tumour within six months of
221 adequate BCG treatment(47). Adequate BCG therapy is defined by at least five out of six induction
222 doses with two out of three maintenance doses, or five induction doses plus two second course
223 induction doses(47).

224 For patients who may not tolerate BCG or are BCG-unresponsive, a novel rescue therapy was proposed
225 by Steinberg in 2015(48). This involved weekly intravesical instillations of gemcitabine immediately
226 followed by docetaxel (Gem/Doce) for six weeks(48). Gemcitabine (a deoxycytidine nucleoside
227 analogue) causes DNA synthesis inhibition, whilst docetaxel (an inhibitor of tubulin dis-assembly)
228 disrupts the cell cycle(48). This combination acts synergistically and leads to apoptosis and reduced
229 cell division, and ultimately tumour cell death.

230 Subsequently, a small clinical trial in 2017, suggested that this combination chemotherapy was safe
231 and effective for patients with high-risk NMIBC who were BCG naïve(49). Steinberg *et al.* performed
232 a retrospective review of patient records at multiple institutions examining the efficacy of
233 Gem/Doce(50). Recurrence-free survival of high-risk disease was 65% at one year and 52% at 2 two
234 years with only 3.3% of patients unable to complete the treatment course due to side-effects(50). This
235 confirmed the potential for Gem/Doce as a rescue therapy following BCG failure, and highlighted the
236 need for further (prospective) studies evaluating this combination therapy.

237

238

239

240 **BCG FUTURE: BUILDING ON THE IMMUNOTHERAPY PARADIGM**

241 The significant reduction in risk of recurrence and progression of NMIBC in patients receiving BCG, has
242 highlighted the importance of immunotherapy for bladder cancer. As understanding of the molecular
243 events and characteristics of various cancers improves(51), more targeted novel therapies are being
244 developed.

245

246 **Immune Checkpoint Inhibitors**

247 There are a plethora of clinical trials evaluating the efficacy of new and more established immune
248 checkpoint inhibitors (ICIs) across multiple haematological and solid organ malignancies. Our
249 understanding of ICIs is still in relative infancy but many are already showing great promise. For
250 example, in the Keynote-057 trial, 101 BCG-unresponsive high-risk NMIBC patients received at least
251 one dose of pembrolizumab during 24 months, or until tumour recurrence, or until dropout due to
252 toxicity/side-effects(52). Keynote-057 found that 41% patients achieved a complete response
253 (absence of recurrent high-risk NMIBC or disease progression) at three months(52), and 46% of those
254 responding remained recurrence and progression free at 12 months(52). Furthermore,
255 pembrolizumab treatment led to a 12-month progression-free survival of 83%(52). Despite inferiority
256 in oncological outcomes compared to radical cystectomy, the use of pembrolizumab was approved by
257 the FDA in 2017 following these promising data, and it is currently used in clinical practice. However,
258 more studies are required to determine optimum treatment regimes. More recently, and for BCG-
259 naïve high-risk NMIBC patients, the POTOMAC study assessed the efficacy of durvalumab (a PD-L1
260 inhibitor) in combination with BCG, compared to standard BCG therapy alone, in BCG-naïve high-risk
261 NMIBC patients(53). It is anticipated that results from these and other clinical trials will lead to more
262 options and greater success in the management of NMIBC, as stand-alone novel ICI therapy or in
263 combination with BCG.

264

265 **Toll-like Receptor Agonists**

266 BCG immunotherapy is thought to act, at least in part, through interactions with three toll-like
267 receptors (TLRs); TLR2, TLR4 and TLR9(54).

268 Toll-like receptors are a large family of cell membrane-spanning proteins that mediate multiple
269 intracellular mechanisms and pathways vital to the innate immune system. Agonists of TLRs have been
270 shown to possess anti-tumour activity across multiple malignancies(55), including, for example, the
271 TLR7 agonist Imiquimod, already in clinical use for basal cell carcinoma and some penile cancers(56).

272 Importantly for bladder cancer, TLRs are present in urothelium, and although their expression may ~~be~~
273 decrease in bladder tumours, their activity has been shown to persist(54). Therefore, TLR agonists
274 appear an attractive target in bladder cancer, and as such, agonists of TLR2, TLR4, TLR7 and TLR9 have
275 been investigated for anti-tumour effects in in-vitro and in-vivo bladder models(54). A small first phase
276 clinical trial of intravesical Imiquimod determined it was safe and had low systemic absorption and
277 toxicity(57). However, further studies are required to establish the optimal TLR(s) to target for NMIBC,
278 and thenceforth desired effects on bladder tumour recurrence or progression to MIBC.

279 An alternate TLR-mediated immunotherapy is the use of BCG cell wall skeleton (CWS). BCG-CWS is a
280 component of the BCG cell wall that can be produced readily, and provides ligands for TLR2 and
281 TLR4(54). Preliminary investigations have shown growth retardation of bladder tumours when
282 administered intravesically in mice(56). The Morales group demonstrated that for patients who have
283 failed standard BCG therapy, intravesical instillations of such a mycobacterial cell wall-DNA complex
284 possessed anti-tumour activity without significant toxicity or patient side-effects(58). These studies
285 highlight the promise and huge potential of immunotherapy, targeting Toll-Like Receptors, for the
286 management of bladder cancer, whether alone or in combination with BCG.

287

288

289

290 **Other Promising Immunotherapeutic Approaches**

291 Interferon alpha-2b, a recombinant protein immune modulator, has been shown to induce bladder
292 tumour regression in animal studies(59, 60). A subsequent clinical trial of different dosing regimes of
293 Interferon alpha-2b in patients with BCG failure or BCG-unresponsive NMIBC, demonstrated good
294 tolerability and suggested potential benefit in recurrence-free survival(61). This interferon was
295 delivered in the form of a recombinant replication-deficient adenovirus gene vector 'Nadofaragene
296 Firadenovec' (rAd-INF α /Syn3) which stimulates local urothelial INF α -2b production, leading to tumour
297 regression(61). Consequently, a phase three trial recruited patients with BCG-unresponsive NMIBC,
298 who received single intravesical doses of Nadofaragene Firadenovec, repeated at 3, 6 and 9 months,
299 if there was no high-grade recurrence(62). Results were promising, with 53.4% of participants having
300 a complete response (macroscopic tumour resolution) at month three, and 45.5% of patients were
301 recurrence free at 12 months(62). This trial also demonstrated 91.9% 24-month overall survival for
302 those receiving at least one dose, whilst significant side effects were only seen in 2% of patients(62).
303 Therefore, Nadofaragene Firadenovec, as a novel and first-of-its-kind gene therapy, could be
304 considered as a viable alternative for patients who fail to respond to BCG therapy (as an alternative
305 to, or if unfit for, radical cystectomy), or even as a potential first-line treatment, for which further data
306 are imminent.

307 Another trial evaluating a recombinant fusion protein in BCG-unresponsive HR-NMIBC patients is
308 VISTA. This phase III non-randomised trial uses Vicinium, a potent inhibitor of protein synthesis that
309 ultimately induces irreversible cell death. Intravesical Vicinium is administered twice weekly for six
310 weeks then weekly for six weeks (induction), then every two weeks for up to two years
311 (maintenance). The three-month complete response was 42% in patients with CIS, and 68% in
312 patients with HR-NMIBC without CIS. Given these promising early results, Vicinium is undergoing
313 FDA licensing application as a potential alternative to radical cystectomy in BCG-unresponsive
314 patients(63).

315

316 Cancer-specific vaccines have been trialled on a small-scale with intravesical immuno-stimulation by
317 BCG with encouraging results: a non-randomised study investigated 24 NMIBC patients in three
318 groups, receiving either vaccine injection (MAGE-A3) alone, or alongside one of two intravesical BCG
319 combinations(64). All groups seroconverted after the vaccination schedule, and half the participants
320 had detectable cancer-specific T-cells irrespective of group, yet only those receiving BCG had these
321 same T-cells detected in urine. This suggests there may be an enhanced vaccine response via immune-
322 stimulation which may help to localise cancer specific T-cells to the tumour.

323 V γ 9/V δ 2 T-cells are the main T-cell type in peripheral blood, and are involved in mediating immune
324 responses to a variety of diseases(65). V γ 9/V δ 2 T-cells can be activated by pyrophosphate-containing
325 phosphoantigens, and by specific prodrugs(65). Previously, pyrophosphate-containing
326 phosphoantigen use has been limited due to their instability in serum, however, prodrugs have been
327 synthesised that are much more stable in serum, and have also shown successful eradication of
328 bladder cancer cells *in vitro*(65). If these findings can be replicated *in vivo* and in clinical trials, and new
329 immunotherapy targets are identified, the management of NMIBC has a promising future.

330

331 **CONCLUSIONS**

332 Intravesical BCG immunotherapy remains invaluable, and the standard of care for most patients with
333 intermediate- and high-risk NMIBC that do not need or want upfront radical cystectomy. However,
334 with increasing pressure on availability, and treatment failure rates of up to 40%(66), BCG is not the
335 best long-term solution for NMIBC. Fortunately, combination and novel immune- therapies are
336 becoming more refined, with improved efficacy, reduced toxicity, and fewer side-effects. Such
337 treatment options will be become ever more necessary due to the rising incidence of bladder cancer
338 with an ageing population and continued BCG shortages. Therefore, ongoing trials of
339 immunotherapeutic agents and novel means of delivering existing drugs (e.g. MMC) to improve

340 efficacy or decrease toxicity, are particularly important for the future of NMIBC management(42, 67,
341 68).

342

343

344

345 **EXECUTIVE SUMMARY**

346 **History of BCG**

- 347 • The current standard BCG regime of six weeks induction followed by maintenance was
348 developed over the course of many years.

349 **BCG Shortage and different BCG Strains**

- 350 • There has been a worldwide shortage of BCG since 2012 (including crises in 2012 and 2014),
351 with differing efficacy between available BCG strains.

352 **Future directions of BCG treatment**

- 353 • There is the potential to reduce or shorten BCG treatment schedules to decrease BCG usage
354 in a time of continued shortage.
- 355 • BCG in combination with Mitomycin C, which may reduce BCG usage.
- 356 • Alternative therapies to BCG for those who are BCG-unresponsive.

357 **Future of Immunotherapy in NMIBC**

- 358 • Immune system targeting agents such as immune checkpoint inhibitors, toll-like receptor
359 agonists, and cancer-specific vaccines, may prove useful as an adjunct to BCG or in BCG-
360 unresponsive patients.

361

362

363

364 **References**

- 365 1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer Incidence and
366 Mortality: A Global Overview and Recent Trends. *Eur Urol.* 71(1), 96-108 (2017).
- 367 2. Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis
368 and clinical diversity. *Nat Rev Cancer.* 15(1), 25-41 (2015).
- 369 3. Bryan RT, Zeegers MP, van Roekel EH *et al.* A comparison of patient and tumour
370 characteristics in two UK bladder cancer cohorts separated by 20 years. *BJU Int.* 112(2), 169-75
371 (2013).
- 372 4. van Rhijn BW, Burger M, Lotan Y *et al.* Recurrence and progression of disease in non-muscle-
373 invasive bladder cancer: from epidemiology to treatment strategy. *Eur Urol.* 56(3), 430-42 (2009).
- 374 5. Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for
375 elderly cancer patients by stage at diagnosis. *Med Care.* 33(8), 828-41 (1995).
- 376 6. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in
377 invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data
378 advanced bladder cancer (ABC) meta-analysis collaboration. *Eur Urol.* 48(2):202-205; discussion 5-6
379 (2005).
- 380 7. Wallace DM, Bryan RT, Dunn JA, Begum G, Bathers S, West Midlands Urological Research
381 Group. Delay and survival in bladder cancer. *BJU Int.* 89(9), 868-78 (2002).
- 382 8. Babjuk M, Burger M, Comperat E *et al.* EAU Guidelines on Non-muscle-invasive Bladder
383 Cancer (TaT1 and CIS) (2020). [https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Non-](https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Non-muscle-Invasive-Bladder-Cancer-2020.pdf)
384 [muscle-Invasive-Bladder-Cancer-2020.pdf](https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Non-muscle-Invasive-Bladder-Cancer-2020.pdf).
- 385 9. Cherry T. Cancer and Acquired Resistance to Tuberculosis. *The Medical Journal of Australia.*
386 1(23), 372-374 (1925).
- 387 10. Pearl R. Cancer and Tuberculosis. *American Journal of Epidemiology.* 9(1), 97-159 (1929).
- 388 11. Murray JF. A Century of Tuberculosis. *American Journal of Respiratory and Critical Care*
389 *Medicine.* 169(11), 1181-1186 (2004).
- 390 12. Meyer J-P, Persad R, Gillatt DA. Use of Bacille Calmette-Guérin in Superficial Bladder Cancer.
391 *Postgraduate Medical Journal.* 78(922), 449-454 (2002).
- 392 13. Old LJ, Clarke DA, Benacerraf B. Effect of Bacillus Calmette-Guerin Infection on Transplanted
393 Tumours in the Mouse. *Nature.* 184, 291-292 (1959).
- 394 14. Coe JE, Feldman JD. Extracutaneous delayed hypersensitivity, particularly in the guinea-pig
395 bladder. *Immunology.* 10(2), 127-36 (1966).
- 396 15. Zbar B, Tanaka T. Immunotherapy of Cancer: Regression of Tumours after Intralesional
397 Injection of Living Mycobacterium Bovis. *American Association for the Advancement of Science.* 172,
398 271-273 (1971).
- 399 16. deKernion JB, Golub SH, Gupta RK, Silverstein M, Morton DL. Successful transurethral
400 intralesional BCG therapy of a bladder melanoma. *Cancer.* 36(5), 1662-1667 (1975).
- 401 17. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of
402 superficial bladder tumors. *J Urol.* 116(2), 180-3 (1976).
- 403 18. Herr HW, Morales A. History of Bacillus Calmette-Guerin and Bladder Cancer: An
404 Immunotherapy Success Story. *J Urol.* 179(1), 53-56 (2008).
- 405 19. Sylvester RJ, Van Der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces
406 the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published
407 results of randomized clinical trials. *J Urol.* 168(5), 1964-1970 (2002).
- 408 20. Hudson MA, Ratliff TL, Gillen DP, Haaff EO, Dresner SM, Catalona WJ. Single course versus
409 maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective,
410 randomized trial. *J Urol.* 138(2), 295-298 (1987).
- 411 21. Badalament RA, Herr HW, Wong GY *et al.* A prospective randomized trial of maintenance
412 versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. *J*
413 *Clin Oncol.* 5(3), 441-449 (1987).

- 414 22. Lamm DL, Blumenstein BA, Crissman JD *et al.* Maintenance bacillus Calmette-Guerin
415 immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder:
416 a randomized Southwest Oncology Group Study. *J Urol.* 163(4), 1124-1129 (2000).
- 417 23. Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for
418 superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.
419 *J Urol.* 169(1), 90-95 (2003).
- 420 24. Babjuk M, Burger M, Comperat E. EAU Guidelines on Non-Muscle-Invasive Bladder Cancer
421 (TaT1 and CIS) (2018). [https://uroweb.org/wp-content/uploads/EAU-Guidelines-Non-muscle-](https://uroweb.org/wp-content/uploads/EAU-Guidelines-Non-muscle-invasive-Bladder-Cancer-TaT1-CIS-2018.pdf)
422 [invasive-Bladder-Cancer-TaT1-CIS-2018.pdf](https://uroweb.org/wp-content/uploads/EAU-Guidelines-Non-muscle-invasive-Bladder-Cancer-TaT1-CIS-2018.pdf).
- 423 25. Boehm BE, Cornell JE, Wang H *et al.* Efficacy of bacillus Calmette-Guérin Strains for
424 Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis.
425 *J Urol.* 198(3), 503-510 (2017).
- 426 26. D'Andrea D, Gontero P, Shariat SF *et al.* Intravesical bacillus Calmette-Guérin for bladder
427 cancer: are all the strains equal? *Transl Androl Urol.* 8(1), 85-93 (2019).
- 428 27. Meeks JJ, Lerner SP, Svatek RS. Bacillus Calmette-Guérin Manufacturing and SWOG S1602
429 Intergroup Clinical Trial. *J Urol.* 197(3), 538-540 (2017).
- 430 28. Rentsch CA, Birkhäuser FD, Biot C *et al.* Bacillus Calmette-Guérin strain differences have an
431 impact on clinical outcome in bladder cancer immunotherapy. *Eur Urol.* 66(4), 677-688 (2014).
- 432 29. Inamoto T, Ubai T, Nishida T, Fujisue Y, Katsuoka Y, Azuma H. Comparable effect with
433 minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an
434 intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a
435 randomized prospective comparison. *Urol Ann.* 5(1), 7-12 (2013).
- 436 30. Hofbauer SL, Shariat SF, Chase DC *et al.* The Moreau Strain of Bacillus Calmette-Guerin (BCG)
437 for High-Risk Non-Muscle Invasive Bladder Cancer: An Alternative during Worldwide BCG Shortage?
438 *Urol Int.* 96(1), 46-50 (2016).
- 439 31. D'Andrea D, Soria F, Abufaraj M *et al.* Comparative Effectiveness of Intravesical BCG-Tice and
440 BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer. *Clin Genitourin Cancer.* 18(1),
441 20-25 (2020).
- 442 32. Svatek RS, Tangen C, Delacroix S, Lowrance W, Lerner SP. Background and Update for S1602
443 "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming
444 with Intradermal BCG Before Intravesical Therapy for BCG-naïve High-grade Non-muscle-invasive
445 Bladder Cancer. *Eur Urol Focus.* 4(4), 522-524 (2018).
- 446 33. Balar AV. Faced With BCG Shortages, Oncologists Move to Rationing of Care (2019).
447 [https://www.targetedonc.com/view/faced-with-bcg-shortages-oncologists-move-to-rationing-of-](https://www.targetedonc.com/view/faced-with-bcg-shortages-oncologists-move-to-rationing-of-care)
448 [care](https://www.targetedonc.com/view/faced-with-bcg-shortages-oncologists-move-to-rationing-of-care).
- 449 34. Mostafid HA, Redorta JP, Sylvester R, Witjes JA. Therapeutic Options in High-risk Non-
450 muscle-invasive Bladder Cancer During the Current Worldwide Shortage of Bacille
451 Calmette-Guérin. *Eur Urol.* 67(3), 359-360 (2015).
- 452 35. Liu X, Dowell AC, Patel P *et al.* Cytokines as effectors and predictors of responses in the
453 treatment of bladder cancer by bacillus Calmette-Guérin. *Future Oncol.* 10(8), 1443-1456 (2014).
- 454 36. Yasuyo S, Yoshihisa S, Takeshi I. Intravesical instillation therapy with bacillus Calmette-
455 Guérin for superficial bladder cancer: Study of the mechanism of bacillus Calmette-Guérin
456 immunotherapy. *International Journal of Urology.* 14(2), 140-146 (2007).
- 457 37. Fankhauser CD, Teoh JY, Mostafid H. Treatment options and results of adjuvant treatment in
458 nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette-Guérin shortage. *Curr Opin*
459 *Urol.* 30(3), 365-369 (2020).
- 460 38. Tolley DA, Hargreave TB, Smith PH *et al.* Effect of intravesical mitomycin C on recurrence of
461 newly diagnosed superficial bladder cancer: interim report from the Medical Research Council
462 Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). *Br Med J (Clin Res Ed).*
463 296(6639), 1759-1761 (1988).

- 464 39. Verweij J, Pinedo H. Mitomycin C: mechanism of action, usefulness and limitations. *Anti-*
465 *Cancer Drugs*. 1(1), 5-13 (1990).
- 466 40. Slater SE, Patel P, Viney R *et al*. The effects and effectiveness of electromotive drug
467 administration and chemohyperthermia for treating non-muscle invasive bladder cancer. *Ann R Coll*
468 *Surg Engl*. 96(6), 415-419 (2014).
- 469 41. Clinicaltrials.gov. Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in
470 High-risk Non-muscle-invasive Bladder Cancer (FB10) (2018).
471 <https://clinicaltrials.gov/ct2/show/NCT03664869>.
- 472 42. Di Stasi SM, Giannantoni A, Giurioli A *et al*. Sequential BCG and electromotive mitomycin
473 versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. *Lancet*
474 *Oncol*. 7(1), 43-51 (2006).
- 475 43. Lamm DL. Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial
476 bladder cancer. *Clin Infect Dis*. 31 Suppl 3:S86-90 (2000).
- 477 44. Oddens J, Brausi M, Sylvester R *et al*. Final results of an EORTC-GU cancers group
478 randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1
479 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years
480 of maintenance. *Eur Urol*. 63(3), 462-472 (2013).
- 481 45. Grimm MO, van der Heijden AG, Colombel M *et al*. Treatment of High-grade Non-muscle-
482 invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced
483 Number and Standard Dose of BCG Instillations: Results of the European Association of Urology
484 Research Foundation Randomised Phase III Clinical Trial "NIMBUS". *Eur Urol*. 78(5), 690-698 (2020).
- 485 46. Martinez-Pineiro L, Portillo JA, Fernando JM, *al*. E. Maintenance Therapy with 3-monthly
486 Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-
487 muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013. *Eur*
488 *Urol*. 68(2), 256-262 (2015).
- 489 47. Ojea A, Nogueira JL, Solson E. A multicentre, randomised prospective trial comparing three
490 intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus
491 Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin
492 C. *Eur Urol*. 52(5), 1398-1406 (2007).
- 493 48. US Food and Drug Administration. BCG-Unresponsive Nonmuscle Invasive Bladder Cancer:
494 Developing Drugs and Biologics for Treatment (2018).
495 <https://www.fda.gov/media/101468/download>.
- 496 49. Steinberg RL, Thomas LJ, O'Donnell MA, Nepple KG. Sequential Intravesical Gemcitabine and
497 Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer. *Bladder Cancer*. 1(1),
498 65-72 (2015).
- 499 50. Milbar N, Kates M, Chappidi MR *et al*. Oncological Outcomes of Sequential Intravesical
500 Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer. *Bladder Cancer*.
501 3(4), 293-303 (2017).
- 502 51. Steinberg RL, Thomas LJ, Brooks N *et al*. Multi-Institution Evaluation of Sequential
503 Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer. *J Urol*.
504 203(5), 902-909 (2020).
- 505 52. Liu X, Dowell AC, Patel P *et al*. Cytokines as effectors and predictors of
506 responses in the treatment of bladder cancer by bacillus Calmette-Guérin. *Future Oncology*. 10(8),
507 1443-1456 (2014).
- 508 53. Balar AV, Kamat AM, Kulkarni GS *et al*. Pembrolizumab monotherapy for the treatment of
509 high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label,
510 single-arm, multicentre, phase 2 study. *Lancet Oncol*. (2021).
- 511 54. Clinicaltrials.gov. Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to
512 the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer (POTOMAC) (2020).
513 <https://www.clinicaltrials.gov/ct2/show/NCT03528694>.

- 514 55. LaRue H, Ayari C, Bergeron A, Fradet Y. Toll-like receptors in urothelial cells-targets for
515 cancer immunotherapy. *Nat Rev Urol.* 10(9), 537-545 (2013).
- 516 56. Smith M, García-Martínez E, Pitter MR *et al.* Trial Watch: Toll-like receptor agonists in cancer
517 immunotherapy. *Oncoimmunology.* 7(12), e1526250 (2018).
- 518 57. Fuge O, Vasdev N, Allchorne P, Green JA. Immunotherapy for bladder cancer. *Res Rep Urol.*
519 4(7), 65-79 (2015).
- 520 58. Falke J, Lammers RJ, Arentsen HC *et al.* Results of a phase 1 dose escalation study of
521 intravesical TMX-101 in patients with nonmuscle invasive bladder cancer. *J Urol.* 189(6), 2077-2082
522 (2013).
- 523 59. Morales A, Phadke K, Steinhoff G. Intravesical mycobacterial cell wall-DNA complex in the
524 treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed. *J Urol.*
525 181(3), 1040-1045 (2009).
- 526 60. Benedict WF, Tao Z, Kim CS *et al.* Intravesical Ad-IFN α causes marked regression of
527 human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN- α
528 protein. *Mol Ther.* 10(3), 525-532 (2004).
- 529 61. Tao Z, Connor RJ, Ashoori F *et al.* Efficacy of a single intravesical treatment with Ad-IFN/Syn
530 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation.
531 *Cancer Gene Ther.* 13(2), 125-130 (2006).
- 532 62. Shore ND, Boorjian SA, Canter DJ *et al.* Intravesical rAd-IFN α /Syn3 for Patients With High-
533 Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A
534 Phase II Randomized Study. *J Clin Oncol.* 35(30), 3410-3416 (2017).
- 535 63. Boorjian SA, Alemozaffar M, Konety BR *et al.* Intravesical nadofaragene firadenovec gene
536 therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-
537 dose clinical trial. *Lancet Oncol.* 22(1), 107-117 (2021).
- 538 64. Dickstein R, Wu N, Cowan B *et al.* VISTA Phase 3 Trial of Vicinium, An EPCAM-targeted
539 Pseudomonas Exotoxin, In BCG-Unresponsive Non-Muscle Invasive Bladder Cancer. (2018).
540 [https://abstracts.mirrorsmed.org/abstracts/vista-phase-3-trial-vicinium-epcam-targeted-](https://abstracts.mirrorsmed.org/abstracts/vista-phase-3-trial-vicinium-epcam-targeted-pseudomonas-exotoxin-bcg-unresponsive-non)
541 [pseudomonas-exotoxin-bcg-unresponsive-non.](https://abstracts.mirrorsmed.org/abstracts/vista-phase-3-trial-vicinium-epcam-targeted-pseudomonas-exotoxin-bcg-unresponsive-non)
- 542 65. Derre L, Cesson V, Lucca I. Intravesical Bacillus Calmette Guerin Combined with a Cancer
543 Vaccine Increases Local T-Cell Responses in Non-uscle-Invasive Bladder Cancer Patients. *Clinical*
544 *Cancer Research.* 23(3), 717-725 (2017).
- 545 66. Kadri H, Taher TE, Xu Q *et al.* Aryloxy Diester Phosphoramidate Prodrugs of
546 Phosphoantigens (ProPAgens) as Potent Activators of V γ 9/V δ 2 T-Cell Immune Responses. *J Med*
547 *Chem.* 63(19), 11258-11270 (2020).
- 548 67. Alhunaidi O, Zlotta AR. The use of intravesical BCG in urothelial carcinoma of the bladder.
549 *Ecancermedicalscience.* 13: 905 (2019).
- 550 68. Lammers RJ, Witjes JA, Inman BA *et al.* The role of a combined regimen with intravesical
551 chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a
552 systematic review. *Eur Urol.* 60(1), 81-93 (2011).
- 553 69. Kleinmann N, Matin SF, Pierorazio PM *et al.* Primary chemoablation of low-grade upper
554 tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS):
555 an open-label, single-arm, phase 3 trial. *Lancet Oncol.* 21(6), 7767-85 (2020).

557

558 **Reference Annotations**

559 **9. *of interest:** The inverse relationship between cancer and tuberculosis was recognised from
560 epidemiological data. This was the basis for the anti-tumour function of TB.

561

- 562 **17. *of interest:** The first trial of intravesical instillation of BCG was performed. The findings from
563 this small trial were the beginning for clinical development of BCG as a therapeutic agent.
564
- 565 **22. **of considerable interest:** This trial evaluated the efficacy of the maintenance period compared
566 to induction therapy alone. The results showed that outcomes were greatly improved with
567 maintenance therapy.
568
- 569 **36. *of interest:** This trial proved the efficacy of intravesical MMC. This drug has since been used to
570 manage bladder cancer as an alternative to BCG for many years.
571
- 572 **54. *of interest:** This trial investigates the use a PD-1 inhibitor in combination with BCG or stand-
573 alone.
574
- 575 **59. *of interest:** The Morales group showed that using components of BCG intravesically can still
576 produce a response.